MALCOLM BRENNER to Immunity, Cellular
This is a "connection" page, showing publications MALCOLM BRENNER has written about Immunity, Cellular.
Connection Strength
0.125
-
Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998 Nov; 4(11):1253-60.
Score: 0.037
-
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res. 2018 12 15; 24(24):6185-6194.
Score: 0.036
-
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May; 67(5):933-8.
Score: 0.025
-
Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42.
Score: 0.020
-
Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996 Oct; 23(3-4):213-20.
Score: 0.008